No biomarker	Glioblastoma	No biomarker	Glioblastoma	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B
TNFRSF9 elevation	Hepatocellular Cancer	TNFRSF9 elevation	Hepatocellular Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: C3 – Early Trials sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : C3	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: C3 – Early Trials sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : C3

Byvasda (bevacizumab biosimilar)

Associations
(4)